NASDAQ:PULM Pulmatrix (PULM) Stock Price, News & Analysis $2.04 +0.03 (+1.49%) (As of 02:26 PM ET) Add Compare Share Share Today's Range$1.86▼$2.1650-Day Range$1.79▼$2.4052-Week Range$1.55▼$2.75Volume33,564 shsAverage Volume14,291 shsMarket Capitalization$7.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Pulmatrix alerts: Email Address Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. About Pulmatrix Stock (NASDAQ:PULM)Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.Read More PULM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PULM Stock News HeadlinesSeptember 15 at 6:15 AM | americanbankingnews.comStockNews.com Begins Coverage on Pulmatrix (NASDAQ:PULM)September 8, 2024 | americanbankingnews.comPulmatrix (NASDAQ:PULM) Receives New Coverage from Analysts at StockNews.comSeptember 16, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 15, 2024 | finance.yahoo.comPulmatrix Second Quarter 2024 Earnings: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)August 13, 2024 | prnewswire.comPulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateJuly 30, 2024 | money.usnews.comPulmatrix IncJuly 20, 2024 | finance.yahoo.comMNKD Jul 2024 6.000 call (MNKD240726C00006000)July 20, 2024 | finance.yahoo.comMNKD Jul 2024 5.000 put (MNKD240726P00005000)September 16, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 19, 2024 | finance.yahoo.comPulmatrix, Inc. (PULM)May 29, 2024 | prnewswire.comPulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind CorporationMay 22, 2024 | msn.comTezepelumab Shows Potential for COPD, Negative Trial NotwithstandingMay 15, 2024 | finanznachrichten.dePulmatrix Inc.: Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)May 15, 2024 | prnewswire.comPulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)May 12, 2024 | finance.yahoo.comPulmatrix First Quarter 2024 Earnings: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)May 10, 2024 | finanznachrichten.dePulmatrix Inc.: Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comPULM Stock Earnings: Pulmatrix Reported Results for Q1 2024May 10, 2024 | prnewswire.comPulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate UpdateSee More Headlines Receive PULM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/16/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PULM CUSIPN/A CIK1574235 Webwww.pulmatrix.com Phone(781) 357-2333Fax707-525-9906Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,120,000.00 Net Margins-95.18% Pretax Margin-95.18% Return on Equity-46.86% Return on Assets-28.14% Debt Debt-to-Equity RatioN/A Current Ratio6.33 Quick Ratio6.33 Sales & Book Value Annual Sales$7.30 million Price / Sales1.08 Cash FlowN/A Price / Cash FlowN/A Book Value$4.93 per share Price / Book0.44Miscellaneous Outstanding Shares3,650,000Free Float3,520,000Market Cap$7.88 million OptionableNot Optionable Beta0.99 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Teofilo David Raad MBA (Age 54)President, CEO & Director Comp: $577.72kMr. Peter Ludlum CMA (Age 69)MBA, Interim CFO and Principal Accounting & Financial Officer Comp: $510.22kDr. Alexander M. Klibanov Ph.D. (Age 74)Founder Key CompetitorsCue BiopharmaNASDAQ:CUEDaré BioscienceNASDAQ:DAREKALA BIONASDAQ:KALAVYNE TherapeuticsNASDAQ:VYNESurrozenNASDAQ:SRZNView All Competitors PULM Stock Analysis - Frequently Asked Questions How have PULM shares performed this year? Pulmatrix's stock was trading at $1.86 at the start of the year. Since then, PULM shares have increased by 16.1% and is now trading at $2.16. View the best growth stocks for 2024 here. How were Pulmatrix's earnings last quarter? Pulmatrix, Inc. (NASDAQ:PULM) released its quarterly earnings data on Tuesday, August, 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. The biotechnology company earned $1.55 million during the quarter. Pulmatrix had a negative trailing twelve-month return on equity of 46.86% and a negative net margin of 95.18%. When did Pulmatrix's stock split? Shares of Pulmatrix reverse split on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Pulmatrix? Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pulmatrix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX) and Trevena (TRVN). This page (NASDAQ:PULM) was last updated on 9/16/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmatrix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmatrix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PULM Stock Alerts